For the quarter ending 2025-09-30, ANTX had -$217K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -9,353 | -17,111 |
| Stock-based compensation expense | 801 | 4,045 |
| Net accretion of discount on investments | 211 | 742 |
| Prepaid expenses and other assets | -2,513 | 1,160 |
| Accounts payable | 113 | -1,204 |
| Accrued compensation | 545 | -477 |
| Accrued liabilities | -249 | -1,500 |
| Other current liabilities | -534 | -74 |
| Net cash used in operating activities | -6,375 | -18,223 |
| Purchases of investments | 3,890 | 33,973 |
| Maturities of investments | 10,000 | 49,000 |
| Net cash provided by investing activities | 6,110 | 15,027 |
| Proceeds from issuance of common stock under the espp | 48 | 38 |
| Proceeds from exercise of stock options | 0 | 27 |
| Net cash provided by financing activities | 48 | 65 |
| Net (decrease) increase in cash and cash equivalents | -217 | -3,131 |
| Cash and cash equivalents at beginning of period | 21,351 | - |
| Cash and cash equivalents at end of period | 18,003 | - |
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)